AHNAK2

Summary

AHNAK2 (AHNAK nucleoprotein 2, HGNC:20125) is a protein-coding gene on chromosome 14q32.33, encoding Protein AHNAK2 (Q8IVF2).

This gene encodes a large nucleoprotein. The encoded protein has a tripartite domain structure with a relatively short N-terminus and a long C-terminus, separated by a large body of repeats. The N-terminal PSD-95/Discs-large/ZO-1 (PDZ)-like domain is thought to function in the formation of stable homodimers. The encoded protein may play a role in calcium signaling by associating with calcium channel proteins. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 113146 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Charcot-Marie-Tooth disease (Limited, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 2,178 total
• MANE Select transcript: NM_138420

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20125
Approved symbol	AHNAK2
Name	AHNAK nucleoprotein 2
Location	14q32.33
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000185567
Ensembl biotype	protein_coding
OMIM	608570
Entrez	113146

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 retained_intron

ENST00000333244, ENST00000555122, ENST00000555544, ENST00000557457

RefSeq mRNA: 2 — MANE Select: NM_138420 NM_001350929, NM_138420

CCDS: CCDS45177

Canonical transcript exons

ENST00000333244 — 7 exons

Exon	Start	End
ENSE00001433221	104954957	104955141
ENSE00001532525	104978183	104978374
ENSE00002436532	104937253	104954799
ENSE00003520885	104957614	104957672
ENSE00003537837	104956588	104956689
ENSE00003542476	104955483	104955633
ENSE00003573678	104957410	104957508

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 99.70.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.2630 / max 676.9938, expressed in 1420 samples.

FANTOM5 promoters (18 alternative TSS)

Promoter ID	TPM avg	Samples expressed
145155	6.9551	1007
145158	5.4252	1108
145154	2.8975	836
145144	0.9672	372
145157	0.7421	397
145152	0.5306	184
145159	0.3062	136
145143	0.2179	93
145151	0.1897	52
145153	0.1889	70

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	99.70	gold quality
upper leg skin	UBERON:0004262	99.40	gold quality
gingival epithelium	UBERON:0001949	98.94	gold quality
skin of hip	UBERON:0001554	98.93	gold quality
gingiva	UBERON:0001828	98.89	gold quality
nipple	UBERON:0002030	98.84	gold quality
skin of leg	UBERON:0001511	98.77	gold quality
dorsal root ganglion	UBERON:0000044	98.73	gold quality
skin of abdomen	UBERON:0001416	98.73	gold quality
zone of skin	UBERON:0000014	98.72	gold quality
mucosa of stomach	UBERON:0001199	98.42	gold quality
upper arm skin	UBERON:0004263	98.33	gold quality
tongue squamous epithelium	UBERON:0006919	97.92	gold quality
mammalian vulva	UBERON:0000997	97.87	gold quality
lower esophagus mucosa	UBERON:0035834	97.79	gold quality
penis	UBERON:0000989	97.45	gold quality
tendon	UBERON:0000043	97.20	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.01	gold quality
saphenous vein	UBERON:0007318	96.85	gold quality
hair follicle	UBERON:0002073	96.82	gold quality
lower esophagus	UBERON:0013473	96.76	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.74	gold quality
calcaneal tendon	UBERON:0003701	96.66	gold quality
esophagus	UBERON:0001043	96.64	gold quality
esophagus mucosa	UBERON:0002469	96.60	gold quality
ectocervix	UBERON:0012249	96.06	gold quality
trigeminal ganglion	UBERON:0001675	95.80	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.70	gold quality
decidua	UBERON:0002450	95.63	gold quality
uterine cervix	UBERON:0000002	95.61	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	668.64
E-ANND-3	yes	10.18
E-CURD-53	no	774.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting AHNAK2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-670-3P	99.03	68.88	2404
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-218-1-3P	98.63	67.97	832
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-7113-5P	97.88	67.33	1735

Literature-anchored findings (GeneRIF, showing 13)

• Periaxin and AHNAK nucleoprotein 2 form intertwined homodimers through domain swapping (PMID:24675079)
• AHNAK2 is overexpressed in PDAC tissues and is an independent prognostic factor in patients with PDAC. (PMID:28423668)
• The authors reveal that AHNAK2 is upregulated in clear cell renal cell carcinoma cells and hypoxic upregulation of AHNAK2 can drive tumorigenesis and progression by supporting EMT and cancer cell stemness. (PMID:28435451)
• Linkage analysis and whole exome sequencing reveals AHNAK2 as a novel genetic cause for autosomal recessive CMT in a Malaysian family. (PMID:31011849)
• Results illustrated that AHNAK2 was upregulated in UM and plays a promoting role in the proliferation and migration of UM cells possibly via regulating PI3K signaling pathway. (PMID:31621397)
• AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma. (PMID:32904605)
• Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma. (PMID:33000678)
• Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma. (PMID:33168407)
• AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis. (PMID:33218938)
• Silencing of AHNAK2 restricts thyroid carcinoma progression by inhibiting the Wnt/beta-catenin pathway. (PMID:34374294)
• AHNAK2 promotes thyroid carcinoma progression by activating the NF-kappaB pathway. (PMID:34627772)
• AHNAK2 Promotes the Progression of Differentiated Thyroid Cancer through PI3K/AKT Signaling Pathway. (PMID:36089788)
• Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. (PMID:37349884)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ahnak2	ENSMUSG00000118667
rattus_norvegicus	Ahnak2	ENSRNOG00000065195
caenorhabditis_elegans		WBGENE00011833

Paralogs (2): PRX (ENSG00000105227), AHNAK (ENSG00000124942)

Protein

Protein identifiers

Protein AHNAK2 — Q8IVF2 (reviewed: Q8IVF2)

All UniProt accessions (1): Q8IVF2

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Homodimer (via PDZ domain). Interacts with DYSF; the interaction is direct and Ca(2+)-independent.

Subcellular location. Nucleus.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8IVF2-1	1	yes
Q8IVF2-2	2
Q8IVF2-3	3

RefSeq proteins (2): NP_001337858, NP_612429* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001478	PDZ	Domain
IPR036034	PDZ_sf	Homologous_superfamily
IPR052082	Myelin_sheath_structural	Family

UniProt features (134 total): sequence variant 41, modified residue 35, compositionally biased region 23, region of interest 15, sequence conflict 8, strand 5, helix 2, splice variant 2, chain 1, domain 1, cross-link 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4CN0	X-RAY DIFFRACTION	1.75

Predicted structure (AlphaFold)

No AlphaFold model available for Q8IVF2 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (36): 280, 294, 593, 842, 1007, 1112, 1337, 1418, 1502, 1510, 1667, 1832, 1840, 2162, 2243, 2408, 2492, 2500, 2738, 2822 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 125 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, KOBAYASHI_EGFR_SIGNALING_24HR_UP, WALLACE_PROSTATE_CANCER_RACE_UP, CHANDRAN_METASTASIS_DN, BILD_HRAS_ONCOGENIC_SIGNATURE, RICKMAN_METASTASIS_DN, ONKEN_UVEAL_MELANOMA_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, BROWNE_HCMV_INFECTION_14HR_DN, GOBP_RNA_SPLICING, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, COATES_MACROPHAGE_M1_VS_M2_DN

GO Biological Process (1): regulation of RNA splicing (GO:0043484)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), T-tubule (GO:0030315), sarcolemma (GO:0042383)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
RNA splicing	1
regulation of gene expression	1
regulation of primary metabolic process	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1
sarcolemma	1
plasma membrane	1

Protein interactions and networks

STRING

2530 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AHNAK2	ACTN1	P12814	585
AHNAK2	ANXA2	P07355	553
AHNAK2	CACNA1S	Q13698	551
AHNAK2	DYSF	O75923	485
AHNAK2	CAV1	Q03135	478
AHNAK2	MYOF	Q9NZM1	452
AHNAK2	S100B	P04271	451
AHNAK2	MUC16	Q8WXI7	446
AHNAK2	FZD1	Q9UP38	439
AHNAK2	LMO7	Q8WWI1	435
AHNAK2	CTNNA1	P35221	426
AHNAK2	KCNV2	Q8TDN2	422
AHNAK2	J3KSM2	J3KSM2	415
AHNAK2	USP17L11	C9JVI0	415
AHNAK2	CAPN3	P20807	413

IntAct

97 interactions, top by confidence:

A	B	Type	Score
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
GJB7	PALM3	psi-mi:“MI:0914”(association)	0.530
PCK2	IGHA1	psi-mi:“MI:0914”(association)	0.530
FKBP11	ANKRD13D	psi-mi:“MI:0914”(association)	0.530
EMILIN1	METTL15	psi-mi:“MI:0914”(association)	0.530
AHNAK2		psi-mi:“MI:0407”(direct interaction)	0.440
AHNAK2	P4	psi-mi:“MI:0407”(direct interaction)	0.440
AHNAK2	FZD7	psi-mi:“MI:0407”(direct interaction)	0.440
SLCO1C1	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
TAMALIN	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
ABCC4	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGEF16	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
ASIC3	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
ATP2B4	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
CYSLTR2	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
DGKK	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
DGKZ	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
DOCK4	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
FRMPD4	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
E6	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440
ORF putative E6	AHNAK2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (192): AHNAK2 (Two-hybrid), AHNAK2 (Two-hybrid), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Co-fractionation), AHNAK2 (Co-fractionation), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS), AHNAK2 (Affinity Capture-MS)

ESM2 similar proteins: A2TJV2, A4FU49, A5D7L8, A6H8Y1, D3YVF0, D3YZV8, F6QRE9, O15069, O43493, P0C2X8, P0C7A2, P21263, P24587, P49919, P62521, Q08DY0, Q0P6D6, Q13127, Q28139, Q28181, Q2T9N0, Q4R729, Q5H9T9, Q5RHP9, Q5STT6, Q5XGC9, Q5XHX6, Q62170, Q63560, Q66H38, Q6AXX0, Q6P5H2, Q6P902, Q70KF4, Q7TSJ2, Q8C627, Q8IVF2, Q8N1P7, Q8N2N9, Q8N3D4

Diamond homologs: E1BM58, O55103, Q63425, Q8IVF2, Q9BXM0, Q09666

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

2178 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1497
Likely benign	509
Benign	87

Top pathogenic / likely-pathogenic (0)

SpliceAI

1642 predictions. Top by Δscore:

Variant	Effect	Δscore
14:104957407:CA:C	donor_loss	1.0000
14:104957408:A:AC	donor_gain	1.0000
14:104957408:ACCTG:A	donor_loss	1.0000
14:104957409:C:A	donor_loss	1.0000
14:104957409:C:CC	donor_gain	1.0000
14:104957504:GTCAC:G	acceptor_gain	1.0000
14:104957505:TCAC:T	acceptor_gain	1.0000
14:104957506:CAC:C	acceptor_gain	1.0000
14:104957506:CACC:C	acceptor_gain	1.0000
14:104957507:AC:A	acceptor_gain	1.0000
14:104957508:CC:C	acceptor_gain	1.0000
14:104957509:C:A	acceptor_loss	1.0000
14:104957509:C:CC	acceptor_gain	1.0000
14:104957510:T:G	acceptor_loss	1.0000
14:104957513:C:CT	acceptor_gain	1.0000
14:104957514:G:T	acceptor_gain	1.0000
14:104957595:T:TA	donor_gain	1.0000
14:104957608:A:AC	donor_gain	1.0000
14:104957609:C:CC	donor_gain	1.0000
14:104957612:A:AC	donor_gain	1.0000
14:104957613:C:CC	donor_gain	1.0000
14:104957613:CAGA:C	donor_gain	1.0000
14:104954750:T:TA	donor_gain	0.9900
14:104954958:T:TA	donor_gain	0.9900
14:104955436:T:TA	donor_gain	0.9900
14:104955485:T:A	donor_gain	0.9900
14:104955518:T:TA	donor_gain	0.9900
14:104955522:TCAGC:T	donor_gain	0.9900
14:104955630:CAGC:C	acceptor_gain	0.9900
14:104956601:AT:A	donor_gain	0.9900

AlphaMissense

38092 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:104955536:A:T	V138D	0.992
14:104954668:C:A	W261C	0.991
14:104954668:C:G	W261C	0.991
14:104954670:A:G	W261R	0.989
14:104954670:A:T	W261R	0.989
14:104955566:A:T	V128D	0.988
14:104955075:A:G	L178P	0.987
14:104954659:A:C	F264L	0.986
14:104954659:A:T	F264L	0.986
14:104954661:A:G	F264L	0.986
14:104939269:G:C	F5394L	0.985
14:104939269:G:T	F5394L	0.985
14:104939271:A:G	F5394L	0.985
14:104939300:A:T	V5384D	0.985
14:104955045:A:G	F188S	0.985
14:104955084:A:G	L175P	0.982
14:104955088:C:G	A174P	0.981
14:104939270:A:G	F5394S	0.979
14:104955051:A:T	V186D	0.979
14:104955078:A:G	I177T	0.979
14:104955573:A:C	Y126D	0.979
14:104978223:G:C	F5L	0.979
14:104978223:G:T	F5L	0.979
14:104978225:A:G	F5L	0.979
14:104939322:A:G	W5377R	0.978
14:104939322:A:T	W5377R	0.978
14:104955132:A:G	L159P	0.978
14:104956639:C:A	W88C	0.978
14:104956639:C:G	W88C	0.978
14:104955491:A:G	L153S	0.977

dbSNP variants (sampled 300 via entrez): RS1000017659 (14:104971341 A>G), RS1000059318 (14:104965219 G>T), RS1000154960 (14:104969318 C>A,T), RS1000183499 (14:104973262 G>A), RS1000240348 (14:104969987 T>C), RS1000242251 (14:104973078 C>A), RS1000281306 (14:104957819 G>A), RS1000385234 (14:104980056 C>T), RS1000435007 (14:104968284 G>A), RS1000442358 (14:104974900 C>T), RS1000471753 (14:104974665 CTCCCAGG>C), RS1000527300 (14:104972248 C>G,T), RS1000579284 (14:104978645 C>T), RS1000579841 (14:104971894 G>A), RS1000633466 (14:104977373 T>G)

Disease associations

OMIM: gene MIM:608570 | disease phenotypes: MIM:160120

GenCC curated gene-disease

Disease	Classification	Inheritance
Charcot-Marie-Tooth disease	Limited	Autosomal recessive

Mondo (3): migraine disorder (MONDO:0005277), hereditary episodic ataxia (MONDO:0016227), Charcot-Marie-Tooth disease (MONDO:0015626)

Orphanet (1): Hereditary episodic ataxia (Orphanet:211062)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002318_173	Rheumatoid arthritis	3.000000e-07
GCST002318_88	Rheumatoid arthritis	5.000000e-08
GCST003599_4	Systemic lupus erythematosus	9.000000e-07
GCST006959_183	Rheumatoid arthritis	7.000000e-06
GCST006959_95	Rheumatoid arthritis	4.000000e-06
GCST007002_7	Cerebrospinal fluid t-tau levels in normal cognition	7.000000e-09
GCST007007_3	Cerebrospinal fluid t-tau levels	7.000000e-06
GCST011956_143	Systemic lupus erythematosus	3.000000e-30

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004760	t-tau measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D002607	Charcot-Marie-Tooth Disease	C10.500.300.200; C10.574.500.495.200; C10.668.829.800.300.200; C16.131.666.300.200; C16.320.400.375.200
D008881	Migraine Disorders	C10.228.140.546.399.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

95 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects cotreatment, increases expression, affects expression, decreases expression	7
bisphenol A	affects cotreatment, decreases expression, affects expression, increases expression	5
Particulate Matter	increases expression, decreases expression, increases abundance, affects cotreatment	4
sodium arsenite	increases abundance, increases expression, affects binding, increases reaction, affects cotreatment (+1 more)	3
bisphenol S	affects cotreatment, decreases expression, affects expression, increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	3
Doxorubicin	affects expression, increases expression	3
perfluorooctane sulfonic acid	increases expression, decreases expression	2
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
Vorinostat	decreases expression	2
Air Pollutants	decreases expression, increases abundance, affects cotreatment	2
Estradiol	affects expression, increases expression	2
Cadmium Chloride	increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
propionaldehyde	increases expression	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression	1
quercitrin	increases expression	1
trichostatin A	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
arsenite	decreases reaction, affects binding	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7JV	Ubigene A-549 AHNAK2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

359 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00174395	PHASE4	COMPLETED	A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
NCT00208065	PHASE4	COMPLETED	Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers
NCT00210496	PHASE4	COMPLETED	Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
NCT00210509	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
NCT00212810	PHASE4	COMPLETED	Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
NCT00212823	PHASE4	COMPLETED	The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain
NCT00216736	PHASE4	COMPLETED	Oral Dexamethasone for Treatment of Migraine
NCT00259636	PHASE4	WITHDRAWN	Zonisamide for Fibromyalgia & Migraine
NCT00259649	PHASE4	COMPLETED	Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
NCT00297375	PHASE4	COMPLETED	A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
NCT00335777	PHASE4	COMPLETED	A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
NCT00363506	PHASE4	UNKNOWN	American Migraine Prevention Study
NCT00364806	PHASE4	COMPLETED	Prochlorperazine vs Metoclopramide
NCT00391755	PHASE4	TERMINATED	A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
NCT00397254	PHASE4	COMPLETED	Two Rizatriptan Prescribing Portions for Treatment of Migraine
NCT00443352	PHASE4	COMPLETED	A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache
NCT00449787	PHASE4	COMPLETED	Comparing Naproxen to Sumatriptan for Emergency Headache Patients
NCT00632385	PHASE4	COMPLETED	Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
NCT00634985	PHASE4	COMPLETED	Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
NCT00637286	PHASE4	COMPLETED	ZAP, US. Zomig for Appropriate for Primary Care
NCT00753311	PHASE4	COMPLETED	Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.
NCT00792636	PHASE4	COMPLETED	A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
NCT00799045	PHASE4	COMPLETED	Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects
NCT00812214	PHASE4	COMPLETED	Treatment of Insomnia in Migraineurs
NCT00846495	PHASE4	COMPLETED	Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
NCT00893737	PHASE4	COMPLETED	Completeness of Response Following Treatment With Treximet™ for Migraine
NCT00910689	PHASE4	COMPLETED	Drug and Non-Drug Treatment Of Severe Migraine
NCT00915473	PHASE4	COMPLETED	Greater Occipital Nerve Block for Migraine Prophylaxis
NCT01016834	PHASE4	COMPLETED	Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
NCT01057160	PHASE4	COMPLETED	Rizatriptan 10 MG RPD in the Treatment of Acute Migraine
NCT01060111	PHASE4	COMPLETED	An Efficacy and Tolerability Study of Topiramate in Participants With Migraine
NCT01071096	PHASE4	COMPLETED	Calcitonin Gene-related Peptide Levels in Chronic Migraine
NCT01071317	PHASE4	COMPLETED	Trial of Comprehensive Migraine Intervention
NCT01090050	PHASE4	COMPLETED	Treximet in the Treatment of Chronic Migraine
NCT01138150	PHASE4	COMPLETED	Ictal and Interictal Inflammatory Markers in Migraine
NCT01211145	PHASE4	COMPLETED	Zomig - Treatment of Acute Migraine Headache in Adolescents
NCT01267864	PHASE4	COMPLETED	Valproate Versus Ketorolac Versus Metoclopramide
NCT01300546	PHASE4	COMPLETED	Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
NCT01319825	PHASE4	UNKNOWN	Preventive Treatment of Episodic and Chronic Migraine
NCT01332864	PHASE4	COMPLETED	Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache